Wickline Mihkai M, Carpenter Paul A, Harris Jeffrey R, Iribarren Sarah J, Reding Kerryn W, Pike Kenneth C, Lee Stephanie J, Lee Catherine J, Oshima Masumi Ueda, Vo Phuong T, Berry Donna L
Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle, Washington.
University of Washington School of Medicine/Fred Hutchinson Cancer Center, Seattle, Washington.
Transplant Cell Ther. 2024 Dec;30(12):1221.e1-1221.e13. doi: 10.1016/j.jtct.2024.09.012. Epub 2024 Sep 19.
Comprehensive survivorship care after hematopoietic cell transplantation (HCT) includes revaccination to restore immunity to vaccine-preventable diseases (VPDs). There is complexity to revaccination in this setting, and revaccination rates are sub-optimal. HCT survivors are at high-risk for morbidity and mortality from infections including VPDs, underscoring the importance of interventions to improve revaccination rates among survivors. Determining associations between survivor characteristics and revaccination uptake may guide interventions. The overall study objective was to advance our understanding of factors influencing revaccination uptake among adult HCT survivors living in the United States The specific study aims were to: (1) determine the prevalence of adult survivors who are completely, partially, or not revaccinated at 2 to 8 years after HCT and (2) examine associations between demographic variables, social determinants of health, clinical variables, past vaccination behaviors, vaccine hesitancy (Vaccination Confidence Scale), and revaccination status in adult HCT survivors. This study employed a one-time cross-sectional revaccination survey of adults who were surviving 2 to 8 years after HCT and living in the United States. The survey was sent to eligible survivors in the Fred Hutchinson Cancer Center Long-term Follow-up research cohort. The point prevalence of revaccination outcomes was determined from all the respondents (n = 338), differences in intent to revaccinate for people not yet fully revaccinated were explored using Fisher's exact test (n = 126), and associations were examined between revaccination outcomes and predictors using multivariable logistic regression (n = 292). Survey response rate was 30%. Among respondents, 62% were completely revaccinated, 33% were partially revaccinated, and 4% were not revaccinated. Most respondents (77%) who were not yet fully revaccinated planned to complete the revaccination protocol. However, fewer not-revaccinated respondents than partially revaccinated respondents planned to complete revaccination (50% versus 80%, P = .032). Factors associated with incomplete revaccination were shorter time from HCT, inadequate immune reconstitution, and not having received all childhood vaccines as a child. Our analysis has identified multiple variables associated with revaccination outcomes, indicating the potential for interventions to enhance post-HCT revaccination rates. Since many survivors cannot be revaccinated promptly due to delayed immune recovery, clinicians should iteratively re-evaluate for revaccination readiness as long as it takes to ensure eventual revaccination. Broader efforts by the healthcare community to increase childhood vaccine uptake might eventually support revaccination uptake. Future research that builds on these findings should focus on intervention testing.
造血细胞移植(HCT)后的综合生存护理包括重新接种疫苗,以恢复对疫苗可预防疾病(VPDs)的免疫力。在这种情况下,重新接种疫苗存在复杂性,且重新接种率未达最佳水平。HCT幸存者因包括VPDs在内的感染而面临较高的发病和死亡风险,这凸显了采取干预措施提高幸存者重新接种率的重要性。确定幸存者特征与重新接种疫苗接受情况之间的关联可能会为干预措施提供指导。本研究的总体目标是增进我们对影响美国成年HCT幸存者重新接种疫苗接受情况的因素的理解。具体研究目标如下:(1)确定成年幸存者在HCT后2至8年完全、部分或未重新接种疫苗的比例,以及(2)研究成年HCT幸存者的人口统计学变量、健康的社会决定因素、临床变量、既往疫苗接种行为、疫苗犹豫(疫苗信心量表)与重新接种疫苗状况之间的关联。本研究对在美国生活且HCT后存活2至8年的成年人进行了一次性横断面重新接种疫苗调查。该调查被发送至弗雷德·哈钦森癌症中心长期随访研究队列中的符合条件的幸存者。根据所有受访者(n = 338)确定重新接种疫苗结果的时点患病率,使用Fisher精确检验探索尚未完全重新接种疫苗者重新接种疫苗意愿的差异(n = 126),并使用多变量逻辑回归研究重新接种疫苗结果与预测因素之间的关联(n = 292)。调查回复率为30%。在受访者中,62%已完全重新接种疫苗,33%部分重新接种疫苗,4%未重新接种疫苗。大多数尚未完全重新接种疫苗的受访者(77%)计划完成重新接种疫苗方案。然而,计划完成重新接种疫苗的未重新接种疫苗的受访者少于部分重新接种疫苗的受访者(50%对80%,P = .032)。与未完全重新接种疫苗相关的因素包括HCT后时间较短、免疫重建不足以及儿童时期未接种所有儿童疫苗。我们的分析确定了多个与重新接种疫苗结果相关的变量,表明有可能采取干预措施提高HCT后的重新接种率。由于许多幸存者因免疫恢复延迟而无法及时重新接种疫苗,临床医生应反复重新评估其重新接种疫苗的准备情况,直至确保最终重新接种。医疗保健界为提高儿童疫苗接种率所做的更广泛努力最终可能会支持重新接种疫苗的接受情况。基于这些发现的未来研究应侧重于干预测试。